Alessandro Federico Selected Research

Alessandro Federico Research Topics

Disease

22	Non-alcoholic Fatty Liver Disease 01/2022 - 07/2005
19	Fibrosis (Cirrhosis) 01/2022 - 09/2007
17	Liver Diseases (Liver Disease) 01/2022 - 01/2003
10	Inflammation (Inflammations) 06/2022 - 12/2007
10	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 09/2007
9	Neoplasms (Cancer) 08/2020 - 12/2007
7	Infections 08/2020 - 07/2012
6	Insulin Resistance 06/2022 - 05/2012
6	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 04/2015
4	Alcoholism (Alcohol Abuse) 05/2021 - 05/2015
4	Necrosis 03/2021 - 03/2010
4	Fatty Liver 01/2018 - 09/2007
3	Alcoholic Fatty Liver 12/2021 - 07/2017
3	Obesity 04/2021 - 01/2019
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 03/2021 - 01/2017
3	Hepatitis 01/2018 - 01/2012
3	Chronic Hepatitis (Chronic Active Hepatitis) 06/2015 - 12/2008
2	Alopecia (Baldness) 03/2021 - 01/2020
2	Pain (Aches) 01/2021 - 09/2008
2	Hypertension (High Blood Pressure) 01/2021 - 01/2017
2	Type 2 Diabetes Mellitus (MODY) 01/2019 - 01/2018
2	Colonic Neoplasms (Colon Cancer) 01/2017 - 01/2014
2	Colorectal Neoplasms (Colorectal Cancer) 01/2017 - 07/2013
2	Body Weight (Weight, Body) 01/2016 - 05/2012
2	Chronic Hepatitis C 01/2016 - 09/2012
1	Dyspepsia (Indigestion) 01/2022
1	COVID-19 04/2021
1	Ischemia 03/2021
1	Breast Neoplasms (Breast Cancer) 03/2021
1	Pruritus (Itching) 01/2021
1	Prolapse 01/2021
1	Hemorrhoids 01/2021
1	Hemorrhage 01/2021
1	Metabolic Diseases (Metabolic Disease) 01/2021
1	Thrombosis (Thrombus) 01/2021
1	Edema (Dropsy) 01/2021
1	Lichen Planus (Lichen Ruber Planus) 12/2020

Drug/Important Bio-Agent (IBA)

11	Silybin (Lagosa)IBA 01/2022 - 09/2007
8	AntioxidantsIBA 03/2021 - 01/2003
7	Antiviral Agents (Antivirals)IBA 05/2020 - 06/2015
7	CytokinesIBA 01/2016 - 01/2005
6	Vitamin E FDA LinkGeneric 01/2021 - 01/2003
5	LipidsIBA 03/2021 - 01/2014
4	Glucose (Dextrose)FDA LinkGeneric 03/2021 - 01/2016
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2020 - 01/2005
4	Ribavirin (Virazole)FDA LinkGeneric 01/2017 - 12/2008
4	InterferonsIBA 01/2017 - 12/2008
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2003
3	Pharmaceutical PreparationsIBA 05/2021 - 03/2008
3	EnzymesIBA 03/2021 - 09/2007
3	Vitamin D FDA LinkGeneric 01/2021 - 01/2019
3	Glutathione (Reduced Glutathione)IBA 01/2021 - 01/2003
3	Phospholipids (Phosphatides)FDA LinkGeneric 01/2021 - 09/2007
3	Biological ProductsIBA 08/2020 - 01/2012
3	urotensin IIIBA 03/2020 - 01/2014
3	Clarithromycin (Biaxin)FDA LinkGeneric 01/2014 - 07/2012
2	Insulin (Novolin)FDA Link 06/2022 - 01/2019
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 12/2020
2	Hormones (Hormone)IBA 03/2021 - 01/2019
2	PhytochemicalsIBA 01/2021 - 02/2017
2	PolyphenolsIBA 01/2021 - 02/2017
2	Alanine Transaminase (SGPT)IBA 12/2020 - 01/2018
2	Thiobarbituric Acid Reactive SubstancesIBA 12/2020 - 01/2019
2	bisphenol AIBA 12/2020 - 01/2019
2	CarcinogensIBA 08/2020 - 07/2013
2	Ethanol (Ethyl Alcohol)IBA 08/2020 - 01/2016
2	Toll-Like Receptors (Toll-Like Receptor)IBA 12/2017 - 01/2016
2	Phosphatidylcholines (Phosphatidylcholine)IBA 07/2017 - 05/2012
2	Messenger RNA (mRNA)IBA 01/2014 - 05/2013
2	Amoxicillin (Wymox)FDA LinkGeneric 07/2013 - 07/2012
2	Immunoglobulin A (IgA)IBA 06/2013 - 09/2012
2	Interleukin-6 (Interleukin 6)IBA 03/2010 - 01/2005
2	S-NitrosothiolsIBA 03/2010 - 01/2005
2	Free RadicalsIBA 12/2007 - 01/2003
1	CalciumIBA 01/2022
1	SodiumIBA 01/2022
1	Bicarbonates (Hydrogen Carbonate)IBA 01/2022
1	MagnesiumIBA 01/2022
1	Sulfates (Sulfates, Inorganic)IBA 01/2022
1	FructoseIBA 04/2021
1	Fatty Acids (Saturated Fatty Acids)IBA 04/2021
1	ResveratrolIBA 03/2021
1	Cetirizine (Zyrtec)FDA LinkGeneric 03/2021
1	palbociclibIBA 03/2021
1	CholesterolIBA 01/2021
1	AldehydesIBA 01/2021
1	Taurocholic Acid (Sodium Taurocholate)IBA 01/2021
1	Glycocholic AcidIBA 01/2021
1	Branched-Chain Amino AcidsIBA 01/2021
1	Diosmin (Daflon)IBA 01/2021
1	Phenylalanine (L-Phenylalanine)FDA Link 01/2021

Therapy/Procedure

23	Therapeutics 01/2022 - 07/2005
3	Drug Therapy (Chemotherapy) 03/2020 - 02/2017
2	Mediterranean Diet 04/2021 - 02/2017
2	Liver Transplantation 03/2021 - 11/2019
2	Duration of Therapy 10/2019 - 07/2013
1	Transjugular Intrahepatic Portasystemic Shunt 12/2021
1	Continuity of Patient Care 09/2021
1	Immunotherapy 09/2021
1	Oral Administration 01/2021